CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 181 enrolled
Drug / intervention
Pneumovax (PPSV23) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00457977
NCT00457977Phase 3Completed
CompareCT.gov

Pneumococcal Vaccine Response in COPD

University of Minnesota·interventional·Posted Apr 9, 2007·Updated May 12, 2015

In Brief

A Phase 3 clinical trial evaluating Pneumovax (PPSV23) and Prevnar (PCV7) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 181 participants across 18 sites.

Detailed Summary

Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease. This study will compare the immune response to two types of pneumococcal vaccines in adults with COPD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2007
Enrollment StartMar 1, 2007
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 19.2 years ago

Interventions

Pneumovax (PPSV23)biological

Injection

Prevnar (PCV7)biological

Injection